Fresenius Medical Care (NYSE:FMS) Now Covered by StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report issued on Saturday. The brokerage set a “strong-buy” rating on the stock.

Separately, Morgan Stanley lowered Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a report on Monday, January 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $32.25.

Fresenius Medical Care Trading Down 3.2 %

NYSE FMS opened at $20.97 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.07 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $12.31 billion, a P/E ratio of 22.79, a PEG ratio of 1.16 and a beta of 0.95. The business has a fifty day simple moving average of $19.62 and a 200 day simple moving average of $19.60. Fresenius Medical Care has a 12 month low of $16.37 and a 12 month high of $27.72.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings results on Tuesday, February 20th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.11. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. The company had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.32 billion. On average, analysts predict that Fresenius Medical Care will post 1.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Pacer Advisors Inc. lifted its stake in shares of Fresenius Medical Care by 14,252.1% during the 4th quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock valued at $10,173,000 after buying an additional 484,998 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Fresenius Medical Care by 362.2% during the third quarter. Envestnet Asset Management Inc. now owns 259,033 shares of the company’s stock worth $5,580,000 after acquiring an additional 202,991 shares in the last quarter. Moran Wealth Management LLC bought a new position in shares of Fresenius Medical Care in the fourth quarter worth $3,247,000. Guardian Capital Advisors LP grew its position in shares of Fresenius Medical Care by 16.7% in the fourth quarter. Guardian Capital Advisors LP now owns 123,715 shares of the company’s stock valued at $2,556,000 after purchasing an additional 17,725 shares in the last quarter. Finally, Partnership Wealth Management LLC bought a new stake in shares of Fresenius Medical Care during the 4th quarter valued at $2,340,000. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.